Key Points
- CFO Aaron Tachibana sold 103,668 shares on Nov. 25 at an average price of $10.78 for about $1.12M, leaving him with 164,458 shares and a 38.66% reduction in his stake.
- Personalis reported a Q that beat estimates with (‑$0.24) EPS vs. (‑$0.28) expected and revenue of $14.5M (vs. $13.31M), but the company still shows a negative ROE (38.25%) and a deeply negative net margin (‑106.92%).
- Analysts have raised price targets recently and the stock holds an average consensus rating of "Moderate Buy" with a $10.29 consensus target, while shares trade around $10.69 (market cap ≈ $949M).
Personalis, Inc. (NASDAQ:PSNL - Get Free Report) CFO Aaron Tachibana sold 103,668 shares of the business's stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the transaction, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Personalis Trading Down 0.3%
Shares of NASDAQ:PSNL opened at $10.69 on Friday. The firm has a market capitalization of $948.83 million, a PE ratio of -12.14 and a beta of 1.92. Personalis, Inc. has a 1-year low of $2.83 and a 1-year high of $11.40. The business's 50 day moving average is $8.38 and its 200-day moving average is $6.55.
Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The firm had revenue of $14.50 million during the quarter, compared to analysts' expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.
Institutional Trading of Personalis
Hedge funds have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in shares of Personalis in the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. acquired a new position in Personalis in the second quarter worth $34,000. BNP Paribas Financial Markets grew its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after purchasing an additional 5,177 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Personalis in the first quarter valued at $47,000. Finally, Alpha Wealth Funds LLC acquired a new position in Personalis during the 2nd quarter worth about $66,000. Institutional investors and hedge funds own 61.91% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently weighed in on PSNL shares. BTIG Research lifted their target price on shares of Personalis from $11.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday, November 11th. Guggenheim raised their price target on shares of Personalis from $6.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, November 11th. Morgan Stanley upped their price objective on Personalis from $5.00 to $9.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 11th. HC Wainwright increased their target price on Personalis from $8.50 to $10.00 and gave the stock a "buy" rating in a report on Thursday, November 6th. Finally, Needham & Company LLC raised their target price on Personalis from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Personalis presently has an average rating of "Moderate Buy" and a consensus price target of $10.29.
Check Out Our Latest Report on Personalis
About Personalis
(
Get Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
